Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP/MTX in Bullous Pemphigoid
NCT02313870Phase 3Completed
- Sponsor
- CHU Montpellier
- Start
- Jan 2008
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in Bullous Pemphigoid (BP) (2 arms), sponsored by CHU Montpellier. Primary endpoint: Actuarial survival rate at 1 year. Started Jan 2008; status: completed.
02
Drugs
methotrexate
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT02313870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313870.